Abstract
This study examines the relationship between R&D intensity, innovation and business performance in the US biotechnology industry. A related objective is to analyse the similarities and differences in innovation strategies, factors affecting business performance, and barriers to innovation in R&D and product/process oriented biotechnology firms. The data for the study are gathered through a postal survey and personal interviews with company personnel involved in R&D. Results show that, during the study period (1993- 1998), R&D intensive firms were successful in obtaining both domestic and international patents as well as contract revenue through licensing agreements. Product/process oriented firms showed some commercial success in that some of them note a growth in pre-tax profit. Both R&D and product/process oriented firms note some differences in rating the importance of specific innovation strategies and barriers. However, both groups agree that quality control is important and collaboration, specifically with university scientists, is important for continued success. All firms rate regulations in the US and in foreign markets as major barriers to innovation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
